drugset / Trial / NCT05184335
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Timeline
- Start
- 2022-01-24
- Primary completion
- 2025-02
- Completion
- 2025-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Brilaroxazine | Small molecule | 15 mg | — |
| Comparator | Brilaroxazine | Small molecule | 30 mg | — |
| Comparator | Brilaroxazine | Small molecule | 50 mg | — |